Ascendis Pharma announced the expiration of the regulatory waiting period for its collaboration agreement with Novo Nordisk, ...

This agreement grants Novo Nordisk an exclusive license to develop and market products targeting obesity and type 2 diabetes, with Ascendis set to receive a $100 million milestone payment ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...

Registered shareholders who are residents of Canada as reflected in the Company’s shareholders register, as well as beneficial Ascendis Pharma (ASND) announced that it has granted Novo Nordisk (NVO) ...

Ascendis Pharma (NASDAQ:ASND) has successfully closed a significant collaboration agreement with Novo Nordisk , following the expiration of a regulatory waiting period. This marks a major step forward ...

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Lead product MBX 2109 is a prodrug of parathyroid hormone (PTH), which is deficient in hypoparathyroidism, and a would rival to Ascendis ... 1/GIP drugs – like Novo Nordisk's semaglutide and ...